Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | Suite 200, 1920 Yonge Street TORONTO ON M4S 3E2 |
Tel: | N/A |
Website: | https://www.promisneurosciences.com |
IR: | See website |
Key People | ||
Eugene Williams Executive Chairman of the Board | Gail M. Farfel Chief Executive Officer, Director | Neil Cashman Co-Founder, Chief Scientific Officer, Director |
Daniel E. Geffken Chief Financial Officer | Gavin Malenfant Chief Operating Officer | Larry Altstiel Chief Medical Officer |
Johanne Kaplan Chief Development Officer | David Wishart Chief Physics Officer |
Business Overview |
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc. |
Financial Overview |
For the nine months ended 30 September 2023, Promis Neurosciences Inc revenues was not reported. Net loss decreased 11% to $9.6M. Lower net loss reflects Research and development - Balancing val decrease of 51% to $4.5M (expense), General and administrative - Balancing v decrease of 17% to $3.9M (expense), Other interest expense decrease from $282K (expense) to $0K. |
Employees: | 6 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16.15M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$18.91M as of Sep 30, 2023 |
Net annual income (TTM): | -$16.90M as of Sep 30, 2023 |
Free cash flow (TTM): | -$11.64M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 18,885,254 as of Nov 10, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |